Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 17, Issue 8, 2018, Pages 681-688

  Ludolph, Albert C ^a,r   Schuster, Joachim ^a   Dorst, Johannes ^a   Dupuis, Luc ^c   Dreyhaupt, Jens ^b   Weishaupt, Jochen H ^a,r   Kassubek, Jan ^a   Weiland, Ulrike ^a,r   Petri, Susanne ^d,r   Meyer, Thomas ^e,r   Grosskreutz, Julian ^f,r   Schrank, Berthold ^g   Boentert, Matthias ^h,r   Emmer, Alexander ^i,r   Hermann, Andreas ^j,r   Zeller, Daniel ^k,r   Prudlo, Johannes ^l,r   Winkler, Andrea S ^m,r   Grehl, Torsten ^n,r   Heneka, Michael T ^o,r   Wollebæk Johannesen, Siw ^p,r   Göricke, Bettina ^q,r   Funke, Andreas ^r   Kettemann, Dagmar ^r   Meyer, Robert ^r   Gruhn, Kai ^r   Schwenkreis, Peter ^r   Stude, Philipp ^r   Kurzwelly, Delia ^r   Storch, Alexander ^r   Richter, Nicole ^r   Frank, Tobias ^r   Hein, Katharina ^r   Hanisch, Frank ^r   Hanke, Dagmar ^r   Kraya, Torsten ^r   Posa, Andreas ^r   Romanakova, Martina ^r   Schilling, Susanne ^r   Abdulla, Susanne ^r   Böselt, Sebastian ^r   Janssen, Claas ^r   Lange, Imken ^r   Kobeleva, Xenia ^r   Körner, Sonja ^r   Kollewe, Katja ^r   Osmanovic, Alma ^r   Scharn, Nicole ^r   Rath, Klaus J ^r   Dahms, Christiane ^r   Gunkel, Anne ^r   Heiling, Bianka ^r   Ringer, Thomas ^r   Smesny, Uta ^r   Baumeister, Sarah ^r   Berthele, Achim ^r   Bublitz, Sarah ^r   Akova Öztürk, Esra ^r   Stubbe Dräger, Bianca ^r   Rahmann, Alexandra ^r   Young, Charlotte ^r   Young, Peter ^r   Baldaranov, Dobri ^r   Bogdahn, Ulrich ^r   Khomenko, Andrei ^r   Schulte Mattler, Wilhelm ^r   Stadler, Christina ^r   Husung, Susanne ^r   Tesar, Simone ^r   Dargah Zaden, Nigar ^r   Last, Christina ^r   Langer, Eva ^r   Lauenstein, Ann Sophie ^r   Lensch, Eckard ^r   Mc Farlane, Carolyn ^r   Fischer Brasse, Heike ^r   Orbán, Klara ^r   Schrank, Bertold ^r   Schürger, Sonja ^r   Klebe, Stephan ^r   Kraft, Peter ^r   Musacchio, Thomas ^r   Seiler, Carola ^r   more..

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g DKD Helios Klinik Wiesbaden   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ RUHR UNIVERSITY BOCHUM   (Germany)

^o UNIVERSITY OF BONN   (Germany)

^p UNIVERSITY OF REGENSBURG   (Germany)

^q UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

RASAGILINE; RILUZOLE; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

ADD ON THERAPY; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BACKACHE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DEPRESSION; DISEASE DURATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; FEMALE; FUNCTIONAL STATUS; HEADACHE; HUMAN; HYPOVENTILATION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SLOW VITAL CAPACITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; AGED; CLINICAL TRIAL; DRUG EFFECT; RETROSPECTIVE STUDY; VITAL CAPACITY;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BODY MASS INDEX; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; RILUZOLE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85048739199     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(18)30176-5     Document Type: Article

References (17)

1. Lacomblez, L, Bensimon, G, Leigh, PN, Guillet, P, Meininger, V, Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 (1996), 1425–1431.
2. Braak, H, Brettschneider, J, Ludolph, AC, Lee, VM, Trojanowski, JQ, Del Tredici, K, Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nat Rev Neurol 9 (2013), 708–714.
3. Schulthess, I, Gorges, M, Muller, HP, et al. Functional connectivity changes resemble patterns of pTDP-43 pathology in amyotrophic lateral sclerosis. Sci Rep, 6, 2016, 38391.
4. Eisen, A, Braak, H, Del Tredici, K, Lemon, R, Ludolph, AC, Kiernan, MC, Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88 (2017), 917–924.
5. Braak, H, Ludolph, AC, Neumann, M, Ravits, J, Del Tredici, K, Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal alpha-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol 133 (2017), 79–90.
6. Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59 (2002), 1937–1943.
7. Olanow, CW, Rascol, O, Hauser, R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 (2009), 1268–1278.
8. Waibel, S, Reuter, A, Malessa, S, Blaugrund, E, Ludolph, AC, Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 251 (2004), 1080–1084.
9. Macchi, Z, Wang, Y, Moore, D, et al. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement. Amyotroph Lateral Scler Frontotemporal Degener 16 (2015), 345–352.
10. Dupuis, L, Dengler, R, Heneka, MT, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One, 7, 2012, e37885.
11. Brooks, BR, Miller, RG, Swash, M, Munsat, TL, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000), 293–299.
12. Castrillo-Viguera, C, Grasso, DL, Simpson, E, Shefner, J, Cudkowicz, ME, Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 11 (2010), 178–180.
13. Fang, T, Al Khleifat, A, Meurgey, JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17 (2018), 416–422.
14. The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group, Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16 (2017), 505–512.
15. Cudkowicz, M, Bozik, ME, Ingersoll, EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 17 (2011), 1652–1656.
16. Cudkowicz, ME, van den Berg, LH, Shefner, JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 12 (2013), 1059–1067.
17. Bozik, ME, Mitsumoto, H, Brooks, BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 406–413.